Verastem, Inc. (LON:0LOV)

Market Cap	600.11M
Revenue (ttm)	9.95M
Net Income (ttm)	-179.37M
Shares Out	n/a
EPS (ttm)	-2.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	322
Average Volume	2,345
Open	10.40
Previous Close	10.04
Day's Range	10.28 - 10.40
52-Week Range	3.51 - 11.17
Beta	n/a
RSI	61.17
Earnings Date	Nov 4, 2025

About Verastem

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2010
• Employees: 78
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0LOV

Financial Performance

Financial numbers in USD